I-Reagent Yokukhishwa Kwesampula
Igama lomkhiqizo
I-Macro & Micro-Test Release Release Reagent
Isitifiketi
I-CE, i-FDA, i-NMPA
Izingxenye eziyinhloko
| Igama | Izingxenye eziyinhloko | Ingxenyeimininingwane | Ubuningi |
| Ukukhishwa Kwesampulai-reagent | I-Dithiothreitol, i-sodium dodecyli-sulfate (SDS), i-RNase inhibitor,i-surfactant, amanzi ahlanzekile | 0.5mL/iVili | Ibhodlela elingu-50 |
Qaphela: Izingxenye ezikuqoqo ezahlukene zamakhithi azikwazi ukushintshaniswa.
Izimo zokugcina kanye nesikhathi sokuphila kweshelufu
Gcina futhi uthuthe ekamelweni lokushisa. Isikhathi sokuphila kweshelufu izinyanga ezingama-24.
Izinsimbi ezisebenzayo
Izinsimbi kanye nemishini ngesikhathi sokucubungula amasampula, njenge-pipettes, i-vortex mixers,amabhavu amanzi, njll.
Izidingo zesampula
Ama-oropharyngeal swabs asanda kuqoqwa, ama-nasopharyngeal swabs.
Ukunemba
Uma le khithi isetshenziselwa ukukhipha ku-CV yereferensi yokunemba yangaphakathi kwamakhophi ayi-10, i-coefficient of variation (CV, %) yenani le-Ct alidluli ku-10%.
Umehluko phakathi kweqembu
Uma ireferensi yokunemba kwangaphakathi ihlolwa kumaqoqo amathathu amakhithi akhiqizwa ngaphansi kokukhiqizwa kwesilingo lapho kukhiqizwa ngokuphindaphindiwe futhi, i-coefficient of variation (CV, %) yenani le-Ct ayidluli ku-10%.
Ukuqhathaniswa kokusebenza
● Ukuqhathaniswa kokusebenza kahle kokukhipha
| Ukuqhathaniswa kokusebenza kahle kwendlela yobuhlalu obunamandla kanye nesampula yokukhulula | ||||
| ukugxilisa ingqondo | indlela yobuhlalu obunamandla | isampula yokukhulula | ||
| i-orfab | N | i-orfab | N | |
| 20000 | 28.01 | 28.76 | 28.6 | 29.15 |
| 2000 | 31.53 | 31.9 | 32.35 | 32.37 |
| 500 | 33.8 | 34 | 35.25 | 35.9 |
| 200 | 35.25 | 35.9 | 35.83 | 35.96 |
| 100 | 36.99 | 37.7 | 38.13 | undet |
Ukusebenza kahle kokukhipha kwesampula yokukhulula kwakufana nendlela yobuhlalu obunamandla, futhi ukuhlushwa kwegciwane kungaba amakhophi angu-200/mL.
● Ukuqhathaniswa kwenani le-CV
| Ukuphindaphindwa kokukhishwa kwesampula yokukhulula | ||
| ukuhlushwa: 5000Amakhophi/mL | I-ORF1ab | N |
| 30.17 | 30.38 | |
| 30.09 | 30.36 | |
| 30.36 | 30.26 | |
| 30.03 | 30.48 | |
| 30.14 | 30.45 | |
| 30.31 | 30.16 | |
| 30.38 | 30.7 | |
| 30.72 | 30.79 | |
| CV | 0.73% | 0.69% |
Lapho kuhlolwa amakhophi angu-5,000 /mL, i-CV ye-orFab ne-N yayingu-0.73% kanye no-0.69% ngokulandelana.
